The Usefulness of PET as a Cancer Screening Test |
Ko, Doo-Heun
(Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Choi, Joon-Young (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Song, Yun-Mi (Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Su-Jin (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Kim, Young-Hwan (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Kyung-Han (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Kim, Byung-Tae (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Moon-Kyu (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) |
1 | Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007;48 Suppl 1:78S-88S |
2 | Bicik I, Bauerfeind P, Breitbach T, von Schulthess GK, Fried M. Inflammatory bowel disease activity measured by positronemission tomography. Lancet 1997;350:262 |
3 | Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med 2007;21:481-98 DOI ScienceOn |
4 | Agress H, Jr., Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004;230:417-22 DOI ScienceOn |
5 | Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. The detection rates and tumor clinical/ pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med 2007;21:65-72 DOI |
6 | Kojima S, Zhou B, Teramukai S, Hara A, Kosaka N, Matsuo Y, et al. Cancer screening of healthy volunteers using whole-body scans: the Nishidai clinic study. Eur J Cancer 2007;43:1842-8 DOI ScienceOn |
7 | Ghotbi N, Iwanaga M, Ohtsuru A, Ogawa Y, Yamashita S. Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure. Asian Pac J Cancer Prev 2007;8:93-7 |
8 | Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging 2006;50:23-7 |
9 | Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in PET and PET/CT oncologic imaging. Semin Nucl Med 2004;34:122-33 DOI ScienceOn |
10 | Weckesser M, Schober O. Is whole-body FDG-PET valuable for health screening? Against. Eur J Nucl Med Mol Imaging 2005; 32:342-3 DOI |
11 | Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 2005;25:1031-43 DOI ScienceOn |
12 | Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, et al. The value of quantifying uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007;28:373-81 DOI ScienceOn |
13 | Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145-55 |
14 | Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-95 DOI ScienceOn |
15 | Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51:1511-20 DOI ScienceOn |
16 | Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med 2005;19:167-77 DOI |
17 | Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, et al. Evaluation of positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 2007; 97:1493-8 DOI ScienceOn |
18 | Kresnik E, Gallowitsch HJ, Mikosch P, Wurtz F, Alberer D, Hebenstreit A, et al. positron emission tomography in the early diagnosis of enterocolitis: preliminary results. Eur J Nucl Med Mol Imaging 2002;29:1389-92 DOI ScienceOn |
19 | Wang G, Lau EW, Shakher R, Rischin D, Ware RE, Hong E, et al. How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT? Cancer 2007;109:117-24 DOI ScienceOn |
20 | Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51; discussion 1520-1 DOI ScienceOn |
21 | Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33; quiz 62-3 |
22 | Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43 DOI ScienceOn |
23 | Basu S, Houseni M, Alavi A. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management. Nucl Med Commun 2008;29:367-73 DOI ScienceOn |
24 | Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34: 274-92 DOI ScienceOn |
25 | Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of positron emission tomography for gastric cancer. World J Surg 2004;28:247-53 DOI |
26 | Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83:1607-11 DOI ScienceOn |
27 | Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46:752-7 |
28 | Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, et al. Focal thyroid lesions incidentally identified by integrated : clinical significance and improved characterization. J Nucl Med 2006;47:609-15 |
29 | Zhuang H, Alavi A. positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59 DOI ScienceOn |
30 | Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S |
31 | Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med 2007;19:495-9 |
32 | Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, Hojgaard L, et al. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 2006;33:697-702 DOI |
33 | Van den Bruel A, Maes A, De Potter T, Mortelmans L, Drijkoningen M, Van Damme B, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 2002;87: 1517-20 DOI |
34 | Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006;9:192-6 DOI |
35 | Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK. uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 2005;115:1074-8 DOI ScienceOn |
36 | 대한핵의학회. 핵의학검사 통계자료(2007){ serial online} {cited 2008 April 1}; Avaliable from:URL: http://www.ksnm.or.kr/member/pds/stat/index.html |
37 | Yasuda S, Shohtsu A. Cancer screening with whole-body positron-emission tomography. Lancet 1997; 350:1819 DOI |
38 | Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4 DOI |
39 | Nam SY, Roh JL, Kim JS, Lee JH, Choi SH, Kim SY. Focal uptake of by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 2007;67:135-9 DOI ScienceOn |
40 | 세계보건기구(WHO). Screening for various cancer{online} {cited 2008 March 31}; Avaliable from:URL: http://www.who.int/cancer/detection/variouscancer/en/index.html |
41 | Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130:941-6 DOI ScienceOn |
42 | Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006;33:541-52 DOI |
43 | 국가암정보센터. 3대 주요암의 5년상대생존율 국제비교{online} {cited 2008 May 14};Avaliable from:URL: http://www.cancer.go.kr/cms/statics/stat/1194001_1611.html |
44 | 세계보건기구(WHO). Screening and early detection of cancer {online}{cited 2008 March 31}; Avaliable from:URL: http://www.who.int/cancer/detection/en |